Mutational Analysis of ZFY in Sporadic Parathyroid Adenomas

Robert Romano,1* La Shondra Ellis,1* Nick Yu,1 Justin Bellizzi,1 Taylor C. Brown,4 Reju Korah,4 Tobias Carling,4 Jessica Costa-Guda,1,3 and Andrew Arnold1,2

1Center for Molecular Medicine, and 2Division of Endocrinology and Metabolism, University of Connecticut School of Medicine, Farmington, Connecticut 06030; 3Center for Regenerative Medicine and Skeletal Development, Department of Reconstructive Sciences, University of Connecticut School of Dental Medicine, Farmington, Connecticut 06030; and 4Yale Endocrine Neoplasia Laboratory, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut 06510

*These authors contributed equally to this study.

Context: The molecular pathogenesis of sporadic parathyroid adenomas is incompletely understood, with alterations in cyclin D1/PRAD1 and MEN1 most firmly established as genetic drivers. The gene encoding the X-linked zinc finger protein (ZFX) has recently been implicated in the pathogenesis of a subset of parathyroid adenomas after recurrent, hotspot-focused somatic mutations were identified. ZFX escapes X inactivation and is transcribed from both alleles in women, and a highly homologous gene encoding the Y-linked zinc finger protein (ZFY) provides dosage compensation in males.

Objective: We sought to investigate the role of ZFY mutation in sporadic parathyroid adenoma.

Intervention: Polymerase chain reaction and Sanger sequencing were used to examine DNA from typically presenting, sporadic (nonfamilial, nonsyndromic) parathyroid adenomas from male patients for mutations within the ZFY gene.

Results: No mutations were identified among 117 adenomas.

Conclusions: The absence of ZFY mutations in this series suggests that ZFY rarely, if ever, acts as a driver oncogene in sporadic parathyroid adenomas. The apparent differences in tumorigenic capabilities between the closely related zinc finger proteins ZFX and ZFY suggest that structure-function studies could represent an opportunity to gain insight into neoplastic processes in the parathyroid glands.

Copyright © 2017 Endocrine Society

This article is published under the terms of the Creative Commons Attribution-Non Commercial License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).

Freeform/Key Words: ZFY, ZFX, parathyroid, oncogene

Single parathyroid adenomas, the most common cause of primary hyperparathyroidism, are well-differentiated, benign, monoclonal tumors that give rise to hypercalcemia through excessive secretion of parathyroid hormone. Recurrent, clonally selected driver mutations in the cyclin D1 proto-oncogene and the MEN1 tumor suppressor gene are established pathogenetic contributors in a subset of these tumors. Additional strong evidence (genetic plus functional) supports lesions of the CDKN1B/p27 cyclin-dependent kinase inhibitor (CDKI) gene, other CDKI genes, and CDC73/HRPT2 as rare genetic contributors to sporadic, nonfamilial parathyroid adenoma formation [1–6], and evidence for the rare involvement of candidate parathyroid oncogenes EZH2 and CTNNB1 has also been reported [7–9]. However, our understanding of the molecular...
Pathogenesis of these tumors remains incomplete. Recently, compelling genetic evidence implicated the X-linked zinc finger protein (ZFX), a Kruppel C2H2-type zinc finger protein that has been reported to have a regulatory role in embryonic stem cell renewal, as a likely driver of parathyroid tumorigenesis. Exome sequencing and subsequent targeted validation sequencing revealed mutations in six of 130 sporadic parathyroid adenomas [10]. These mutations were strikingly specific and restricted in their locations, consistent with hypermorphic or neomorphic function; they affect one of the same two codons, 786 or 787, which encode two highly conserved arginine residues in the functionally critical 13th (C-terminal most) zinc finger domain. All of these substitutions were also predicted, by SIFT, to alter the functionality of the ZFX protein. Importantly, ZFX, situated on the X chromosome, escapes X inactivation and is transcribed from both alleles in females; in males the highly homologous zinc finger protein encoded by the Y chromosome (ZFY) is expressed to provide dosage compensation [11]. ZFX and ZFY are highly homologous, sharing 92% of their protein sequence identities overall, and 97% of their identities in the 13th zinc finger domains [11]; in addition, ZFY, like ZFX, is expressed in many tissues, including the parathyroid glands [12]. Because of the close relationship between these genes, we hypothesized that mutations in ZFY could potentially have a tumorigenic role in hyperparathyroidism similar to that of mutations in ZFX. We also noted that one ZFY mutation has been reported in a colon carcinoma (according to the Catalogue of Somatic Mutations in Cancer). Thus, we sought to investigate the role of ZFY in typically presenting sporadic parathyroid adenomas from male patients.

1. Materials and Methods

A. Patients and Samples

Tumor samples were obtained from 117 male patients who had undergone parathyroidectomy for primary hyperparathyroidism with typical presentations; these tumors were surgically and histopathologically proven as single parathyroid adenomas with no atypical and/or malignant features. No patient had a family and/or personal history that was suggestive of familial and/or syndromic hyperparathyroidism. All samples were obtained with informed consent in accordance with institutional review board–approved protocols. Genomic DNA was extracted from fresh, frozen tissue by proteinase K digestion followed by phenol-chloroform extraction and ethanol precipitation.

B. Polymerase Chain Reaction and Sanger Sequencing

Primers were designed for ZFY’s seven coding exons (Table 1), such that intron regions at the splice junctions were also examined. The polymerase chain reactions (PCRs) were carried out in 20-μL reaction volumes, containing 25 ng of sample DNA, 12 μL of deionized H2O, 2 μL of 10× PCR buffer (Applied Biosystems, Austin, TX), 200 μM of deoxynucleotide triphosphates, 1.2 μL of MgCl2, 1 μM of forward and reverse primer, and 1.5 mM of Taq Gold (Applied Biosystems, Foster City, CA). The PCR reactions were performed by incubating at 95°C for 10 minutes, followed by 35 cycles of 95°C for 30 seconds, 55°C for 30 seconds (60°C for exon 7), and 72°C for 1 minute, and a final elongation step of 72°C for 10 minutes. The PCR products were purified with ExoSAP-IT (Affymetrix, Santa Clara, CA) and were sequenced using standard Sanger sequencing methodology and the same primers used for PCR (GeneWiz, South Plainfield, NJ). Sequence data were analyzed using the Sequencher (Gene Codes, Ann Arbor, MI) DNA sequence analysis software to align sequences obtained from tumor DNA to the reference sequence.

2. Results

A total of 117 parathyroid adenomas were tested for sequence variants in the coding region of ZFY. One variant was found, which represented a single nucleotide polymorphism
In the intronic region preceding exon 5 (Table 1). If the true frequency of ZFY mutation in parathyroid adenoma was comparable to that of ZFX (6 of 130; 4.6%), this sample size of 117 was well powered to detect such mutations, with a statistical power above 80%.

3. Discussion

Recurrent somatic hotspot mutations identified in ZFX have provided compelling genetic evidence implicating the X-linked zinc finger protein in the molecular pathogenesis of parathyroid adenoma [10]. Importantly, ZFX escapes X inactivation and is transcribed from both alleles in women, whereas a highly homologous gene encoding the Y zinc finger protein (ZFY) provides dosage compensation in males [11]. As such, it is quite plausible that ZFY could harbor driver mutations that contribute to the molecular pathogenesis of parathyroid adenomas, similar to mutations found in ZFX.

However, this study did not identify ZFY somatic mutations or sequence variants of likely pathogenicity in any of the 117 parathyroid adenomas that were analyzed. Our sample size was well powered to detect a ZFY mutation if the frequency of such events was similar to that of ZFX, and we therefore conclude that the mutational frequency of ZFY, if mutations occur at all, is likely much lower than that of ZFX. Our observations imply that mutations in ZFY (even those corresponding to the ZFX hotspot) fail to yield a selective advantage to parathyroid cells that may randomly acquire a mutation, and that the few surrounding differences in the sequences of the ZFX and ZFY proteins may be important in determining their relative oncogenicity. Thus, structure-function studies of these proteins and mutations could yield insights into neoplastic mechanisms in the parathyroid cell context.

Acknowledgments

Address all correspondence to: Andrew Arnold, MD, Center for Molecular Medicine, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, Connecticut 06030. E-mail: aarnold@uchc.edu.

This work was supported by the Murray-Heilig Fund in Molecular Medicine.

Disclosure Summary: The authors have nothing to disclose.

References and Notes

1. Costa-Guda J, Arnold A. Genetic and epigenetic changes in sporadic endocrine tumors: parathyroid tumors. Mol Cell Endocrinol. 2014;386(1-2):46–54.
2. Costa-Guda J, Marinoni I, Molatore S, Pellegata NS, Arnold A. Somatic mutation and germline sequence abnormalities in CDKN1B, encoding p27Kip1, in sporadic parathyroid adenomas. J Clin Endocrinol Metab. 2011;96(4):E701–E706.

3. Costa-Guda J, Soong CP, Parekh VI, Agarwal SK, Arnold A. Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic parathyroid adenomas. Horm Cancer. 2013;4(5):301–307.

4. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Höller H, Fend F, Graw J, Atkinson MJ. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA. 2006;103(42):15558–15563.

5. Cetani F, Pardi E, Borsari S, Viacca P, Dipollina G, Cianferotti L, Ambrogini E, Gazzzerro E, Colussi G, Berti P, Miccoli P, Pinchera A, Marcocci C. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab. 2004;89(11):5583–5591.

6. Sulaiman L, Nilsson IL, Juhlin CC, Haglund F, Höög A, Larsson C, Hashemi J. Genetic characterization of large parathyroid adenomas. Endocr Relat Cancer. 2012;19(3):389–407.

7. Starker LF, Fonseca AL, Akerström G, Björklund P, Westin G, Carling T. Evidence of a stabilizing mutation of β-catenin encoded by CTNNB1 exon 3 in a large series of sporadic parathyroid adenomas. Endocrine. 2012;42(3):612–615.

8. Cromer MK, Starker LF, Choi M, Udelsman R, Nelson-Williams C, Lifton RP, Carling T. Identification of somatic mutations in parathyroid tumors using whole-exome sequencing. J Clin Endocrinol Metab. 2012;97(9):E1774–E1781.

9. Svedlund J, Barazeghi E, Stålberg P, Hellman P, Åkerström G, Björklund P, Westin G. The histone methyltransferase EZH2, an oncogene common to benign and malignant parathyroid tumors. Endocr Relat Cancer. 2014;21(2):231–239.

10. Soong CP, Arnold A. Recurrent ZFX mutations in human sporadic parathyroid adenomas. Oncoscience. 2014;1(5):360–366.

11. Schneider-Gädicke A, Beer-Romero P, Brown LG, Nussbaum R, Page DC. ZFX has a gene structure similar to ZFY, the putative human sex determinant, and escapes X inactivation. Cell. 1989;57(7):1247–1258.

12. Uhlén M, Björling E, Agaton C, Szgyarto CA, Amini B, Andersen E, Andersson AC, Angelidou P, Asplund A, Asplund C, Berghult L, Bergström K, Brumer H, Cerjan D, Ekström M, Eloibeid A, Eriksson C, Fagerberg L, Fall K, Fall J, Forsberg M, Björklund MG, Gumbel K, Halimi A, Hallin I, Hamsten C, Hansson M, Hedhammar M, Hercules G, Kampf C, Larsson K, Lindskog M, Lodewyckx W, Lund J, Lundeborg J, Magnusson K, Malm E, Nilsson P, Odling J, Oksvold P, Olsson I, Oster E, Ottosson J, Paavilainen L, Persson A, Rimini R, Rockberg J, Runeson M, Sivertsson A, Sköllermo A, Steen J, Stenvall M, Sterky F, Strömberg S, Sundberg M, Tegel H, Tourle S, Wahland E, Waldén A, Wan J, Wernérus H, Westberg J, Wester K, Wrethagen U, Xu LL, Hober S, Pontén F. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics. 2005;4(12):1920–1932.